Evolent Health, Inc. EVH
We take great care to ensure that the data presented and summarized in this overview for Evolent Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EVH
View all-
Wellington Management Group LLP Boston, MA11.2MShares$260 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.1MShares$257 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.69MShares$202 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.51MShares$198 Million2.45% of portfolio
-
William Blair Investment Management, LLC Chicago, IL5.03MShares$117 Million0.26% of portfolio
-
Jpmorgan Chase & CO New York, NY4.35MShares$101 Million0.01% of portfolio
-
Glenn Welling Engaged Capital LLC | Newport Beach, Ca4.11MShares$95.7 Million14.76% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.08MShares$94.9 Million2.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.74MShares$87 Million1.26% of portfolio
-
Holocene Advisors, LP New York, NY3.08MShares$71.6 Million0.26% of portfolio
Latest Institutional Activity in EVH
Top Purchases
Top Sells
About EVH
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
Insider Transactions at EVH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 23
2024
|
Daniel Joseph Mc Carthy PRESIDENT |
SELL
Open market or private sale
|
Direct |
10,469
-2.67%
|
$335,008
$32.5 P/Share
|
|
Aug 22
2024
|
Jonathan Weinberg General Counsel |
SELL
Open market or private sale
|
Direct |
42,140
-11.16%
|
$1,306,340
$31.0 P/Share
|
|
Aug 22
2024
|
Jonathan Weinberg General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
42,140
+10.01%
|
$632,100
$15.48 P/Share
|
|
Aug 22
2024
|
Daniel Joseph Mc Carthy PRESIDENT |
SELL
Open market or private sale
|
Direct |
23,693
-5.45%
|
$734,483
$31.5 P/Share
|
|
Aug 22
2024
|
Daniel Joseph Mc Carthy PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
4,550
+2.0%
|
$109,200
$24.75 P/Share
|
|
Aug 22
2024
|
John Paul Johnson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
44,693
-20.7%
|
$1,340,790
$30.0 P/Share
|
|
Aug 22
2024
|
Seth Blackley Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
187,904
-31.33%
|
$5,637,120
$30.0 P/Share
|
|
Aug 22
2024
|
Seth Blackley Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
187,904
+10.15%
|
$1,691,136
$9.14 P/Share
|
|
Aug 22
2024
|
Emily Ann Rafferty Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
8,861
-12.26%
|
$265,830
$30.0 P/Share
|
|
Aug 01
2024
|
Aammaad Shams Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,567
-4.67%
|
$56,474
$22.44 P/Share
|
|
Jun 06
2024
|
Mary Bridget Duffy Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,709
+13.84%
|
-
|
|
Jun 06
2024
|
Diane Holder Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,709
+10.2%
|
-
|
|
Jun 06
2024
|
Cheryl Scott Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,709
+13.02%
|
-
|
|
Jun 06
2024
|
Peter J Grua Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,709
+37.67%
|
-
|
|
Jun 06
2024
|
Craig A. Barbarosh Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,709
+20.47%
|
-
|
|
Jun 06
2024
|
Richard M Jelinek Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,709
+34.78%
|
-
|
|
Jun 06
2024
|
Toyin Ajayi Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,709
+38.93%
|
-
|
|
Jun 06
2024
|
Russell Monroe Glass Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,709
+46.49%
|
-
|
|
Jun 06
2024
|
Kim Keck Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,709
+21.01%
|
-
|
|
Mar 02
2024
|
John Paul Johnson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,020
-4.01%
|
$306,680
$34.41 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 461K shares |
|---|---|
| Exercise of conversion of derivative security | 518K shares |
| Payment of exercise price or tax liability | 209K shares |
|---|---|
| Open market or private sale | 470K shares |